Stay updated on SAGE-718 Effects in AD: Mild Cognitive Impairment Clinical Trial
Sign up to get notified when there's something new on the SAGE-718 Effects in AD: Mild Cognitive Impairment Clinical Trial page.

Latest updates to the SAGE-718 Effects in AD: Mild Cognitive Impairment Clinical Trial page
- Check6 days agoChange DetectedThe page has removed the estimated timestamps for when results were first posted and last updated, which may affect users' understanding of the timeliness of the information provided.SummaryDifference0.1%
- Check13 days agoChange DetectedThe page has been updated to reflect an increase in the number of study locations from 36 to 39, and the expected modernization of ClinicalTrials.gov data ingest has been pushed to July 2025. Additionally, there are updates regarding the treatment regimen for participants, including specific dosages of SAGE-718.SummaryDifference28%
- Check20 days agoNo Change Detected
- Check28 days agoChange DetectedThe page has been updated to reflect the submission of results and has been revised to version 2.16.2.SummaryDifference0.2%
- Check35 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check64 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check78 days agoChange DetectedThe page has undergone significant content removal, particularly regarding the study's purpose and detailed inclusion and exclusion criteria for participants with Mild Cognitive Impairment or Mild Dementia due to Alzheimer's Disease. The revision number has also been updated from v2.14.4 to v2.15.0.SummaryDifference23%
Stay in the know with updates to SAGE-718 Effects in AD: Mild Cognitive Impairment Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SAGE-718 Effects in AD: Mild Cognitive Impairment Clinical Trial page.